Pub Date : 2026-08-10DOI: 10.1038/s41582-026-01244-5
Riley Bove, Ruth Dobson
Menopause is under-recognized as a biological and sociocultural contributor to brain health, and scientific understanding of the impact that the menopausal transition has on the brain is minimal. This knowledge gap is particularly detrimental for women who live with neurological conditions. We lack sufficient data to understand the experience of women with established neurological conditions during perimenopause, the mechanisms associated with postmenopausal changes in disease course and how to improve management of neurological conditions in a sex-specific way. Furthermore, approximately two thirds of women experience cognitive concerns during the menopausal transition. Although earlier menopause is associated with a greater risk of cognitive decline, the influence of the menopausal transition on subsequent risk of neurological conditions remains unclear. In this Roadmap, we identify key areas in which research is limited and highlight historical and scientific challenges that have hindered progress in understanding brain health in the context of menopause. To address these challenges, we consider existing knowledge and propose priorities and future research directions to advance our understanding of the relationship between menopause and neurological health and disease. Menopause is under-recognized as a contributor to brain health, and we lack understanding of its interactions with neurological conditions. In this Roadmap, Bove and Dobson identify where research is limited and propose future research directions to further our understanding of the relationship between menopause and neurological health and disease.
{"title":"Menopause and neurological disorders: a roadmap for research","authors":"Riley Bove, Ruth Dobson","doi":"10.1038/s41582-026-01244-5","DOIUrl":"10.1038/s41582-026-01244-5","url":null,"abstract":"Menopause is under-recognized as a biological and sociocultural contributor to brain health, and scientific understanding of the impact that the menopausal transition has on the brain is minimal. This knowledge gap is particularly detrimental for women who live with neurological conditions. We lack sufficient data to understand the experience of women with established neurological conditions during perimenopause, the mechanisms associated with postmenopausal changes in disease course and how to improve management of neurological conditions in a sex-specific way. Furthermore, approximately two thirds of women experience cognitive concerns during the menopausal transition. Although earlier menopause is associated with a greater risk of cognitive decline, the influence of the menopausal transition on subsequent risk of neurological conditions remains unclear. In this Roadmap, we identify key areas in which research is limited and highlight historical and scientific challenges that have hindered progress in understanding brain health in the context of menopause. To address these challenges, we consider existing knowledge and propose priorities and future research directions to advance our understanding of the relationship between menopause and neurological health and disease. Menopause is under-recognized as a contributor to brain health, and we lack understanding of its interactions with neurological conditions. In this Roadmap, Bove and Dobson identify where research is limited and propose future research directions to further our understanding of the relationship between menopause and neurological health and disease.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"581-601"},"PeriodicalIF":31.2,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-08-05DOI: 10.1038/s41582-026-01254-3
Lisa Kiani
A new study reports a CAR T cell therapy that concurrently targets the tumour and the pro-tumour microenvironment through a shared antigen. The new strategy could help to overcome key limitations of current therapies.
{"title":"Tumour and microenvironment targeting of glioblastoma with dual-acting CAR T cells","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01254-3","DOIUrl":"10.1038/s41582-026-01254-3","url":null,"abstract":"A new study reports a CAR T cell therapy that concurrently targets the tumour and the pro-tumour microenvironment through a shared antigen. The new strategy could help to overcome key limitations of current therapies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"544-544"},"PeriodicalIF":31.2,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-08-04DOI: 10.1038/s41582-026-01255-2
Brendan P. Lucey, Michael J. Howell
Sleep disruption in Alzheimer disease has long been viewed as a downstream consequence of amyloid and tau. Two new studies show that glia-mediated mechanisms involving microglia and astrocytic aquaporin 4, rather than amyloid plaque burden, disrupt sleep and are potential targets to prevent Alzheimer disease-related sleep loss.
{"title":"Losing sleep over glia: new mechanisms for Alzheimer-related sleep disruption","authors":"Brendan P. Lucey, Michael J. Howell","doi":"10.1038/s41582-026-01255-2","DOIUrl":"10.1038/s41582-026-01255-2","url":null,"abstract":"Sleep disruption in Alzheimer disease has long been viewed as a downstream consequence of amyloid and tau. Two new studies show that glia-mediated mechanisms involving microglia and astrocytic aquaporin 4, rather than amyloid plaque burden, disrupt sleep and are potential targets to prevent Alzheimer disease-related sleep loss.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"604-605"},"PeriodicalIF":31.2,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-08-03DOI: 10.1038/s41582-026-01248-1
Alexandra Chapleau, Felipe Villa Tobón, Geneviève Bernard
Hereditary white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, are a heterogeneous group of conditions characterized by white matter signal abnormalities on neuroimaging. An increasing number of these disorders are now associated with defects in genes that encode proteins involved in transcription, RNA processing and translation. Pathogenic variants in these genes disrupt fundamental processes of the central dogma yet manifest primarily as neurological diseases, often presenting with diverse clinical and radiological features. Although many of these conditions have been recognized for over a decade, their underlying pathophysiological mechanisms and the selective vulnerability of the CNS and myelin remain incompletely understood. Here we provide a comprehensive overview of white matter disorders arising from defects in protein biosynthesis pathways. We summarize known disease-causing genes and their molecular consequences and associated clinical and radiological phenotypes, and highlight emerging mechanistic themes and therapeutic strategies across this expanding class of disorders. This Review provides a comprehensive overview of white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, that arise from defects in protein biosynthesis pathways. The authors highlight the role of causal genes across transcription, RNA processing and translation and summarize the clinical and radiological features of these disorders, as well as emerging therapeutic strategies.
{"title":"White matter disorders at the intersection of transcription, RNA processing and translation","authors":"Alexandra Chapleau, Felipe Villa Tobón, Geneviève Bernard","doi":"10.1038/s41582-026-01248-1","DOIUrl":"10.1038/s41582-026-01248-1","url":null,"abstract":"Hereditary white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, are a heterogeneous group of conditions characterized by white matter signal abnormalities on neuroimaging. An increasing number of these disorders are now associated with defects in genes that encode proteins involved in transcription, RNA processing and translation. Pathogenic variants in these genes disrupt fundamental processes of the central dogma yet manifest primarily as neurological diseases, often presenting with diverse clinical and radiological features. Although many of these conditions have been recognized for over a decade, their underlying pathophysiological mechanisms and the selective vulnerability of the CNS and myelin remain incompletely understood. Here we provide a comprehensive overview of white matter disorders arising from defects in protein biosynthesis pathways. We summarize known disease-causing genes and their molecular consequences and associated clinical and radiological phenotypes, and highlight emerging mechanistic themes and therapeutic strategies across this expanding class of disorders. This Review provides a comprehensive overview of white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, that arise from defects in protein biosynthesis pathways. The authors highlight the role of causal genes across transcription, RNA processing and translation and summarize the clinical and radiological features of these disorders, as well as emerging therapeutic strategies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"625-651"},"PeriodicalIF":31.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-08-03DOI: 10.1038/s41582-026-01249-0
Alan J. Thompson, Fred D. Lublin, Lindsay Rechtman, James Quinn, Maria Pia Amato, Bruce Bebo, Peter A. Calabresi, Julie Fiol, Marcia Finlayson, Annie Hawton, Tanja Kuhlmann, Ruth Ann Marrie, Marcello Moccia, Xavier Montalban, Michael Panzara, Kathy Smith, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee, on behalf of the 2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis
Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course. The current clinical course descriptors of multiple sclerosis do not capture the full disease spectrum or reflect the underlying biological mechanisms. In this Roadmap, the International Advisory Committee on Clinical Trials in Multiple Sclerosis proposes a roadmap for transitioning towards biologically informed descriptors of the multiple sclerosis disease course.
{"title":"Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition","authors":"Alan J. Thompson, Fred D. Lublin, Lindsay Rechtman, James Quinn, Maria Pia Amato, Bruce Bebo, Peter A. Calabresi, Julie Fiol, Marcia Finlayson, Annie Hawton, Tanja Kuhlmann, Ruth Ann Marrie, Marcello Moccia, Xavier Montalban, Michael Panzara, Kathy Smith, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee, on behalf of the 2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis","doi":"10.1038/s41582-026-01249-0","DOIUrl":"10.1038/s41582-026-01249-0","url":null,"abstract":"Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course. The current clinical course descriptors of multiple sclerosis do not capture the full disease spectrum or reflect the underlying biological mechanisms. In this Roadmap, the International Advisory Committee on Clinical Trials in Multiple Sclerosis proposes a roadmap for transitioning towards biologically informed descriptors of the multiple sclerosis disease course.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"652-660"},"PeriodicalIF":31.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-07-29DOI: 10.1038/s41582-026-01253-4
Tavia E. Evans, Joshua Harper, Aram Salehi, Andrew G. Webb, James H. Cole, Ana Correa, Hieab H. H. Adams, Dave M. Cash, Derek K. Jones
{"title":"Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’","authors":"Tavia E. Evans, Joshua Harper, Aram Salehi, Andrew G. Webb, James H. Cole, Ana Correa, Hieab H. H. Adams, Dave M. Cash, Derek K. Jones","doi":"10.1038/s41582-026-01253-4","DOIUrl":"10.1038/s41582-026-01253-4","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"662-662"},"PeriodicalIF":31.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-07-29DOI: 10.1038/s41582-026-01252-5
Melody T. Asukile, Josemir W. Sander, John S. Duncan
{"title":"Low-field MRI for equitable epilepsy diagnosis in resource-limited settings","authors":"Melody T. Asukile, Josemir W. Sander, John S. Duncan","doi":"10.1038/s41582-026-01252-5","DOIUrl":"10.1038/s41582-026-01252-5","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"661-661"},"PeriodicalIF":31.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-07-28DOI: 10.1038/s41582-026-01250-7
Jesy Nelson, Giles Lomax
Disease-modifying therapies for spinal muscular atrophy have transformed the disease prognosis, yet many children continue to face substantial disability owing to delayed diagnosis. Rapid implementation of newborn screening is imperative to offer life-changing interventions for affected families.
{"title":"Newborn screening is the missing step in spinal muscular atrophy care","authors":"Jesy Nelson, Giles Lomax","doi":"10.1038/s41582-026-01250-7","DOIUrl":"10.1038/s41582-026-01250-7","url":null,"abstract":"Disease-modifying therapies for spinal muscular atrophy have transformed the disease prognosis, yet many children continue to face substantial disability owing to delayed diagnosis. Rapid implementation of newborn screening is imperative to offer life-changing interventions for affected families.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"535-537"},"PeriodicalIF":31.2,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148605480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-07-16DOI: 10.1038/s41582-026-01241-8
Per Borghammer, Nathalie Van Den Berge, Daniela Berg, Ryosuke Takahashi, Ronald B. Postuma, Jacob Horsager
People with Lewy body disease exhibit heterogeneous clinical symptoms, diverse patterns of neurodegeneration on imaging and variable Lewy body pathology at post-mortem. The brain-first versus body-first (BvB) model provides a unifying framework that may account for much of this variability. According to the BvB model, Lewy pathology originates either in autonomic nerves of the gut or other peripheral neurons (body first) or in the olfactory bulb with subsequent spread to the limbic system (brain first). Both subtypes are thought to begin largely outside the CNS, possibly triggered by exogenous factors such as infectious agents or toxins. The model is supported by several observations. First, some individuals develop autonomic dysfunction and sleep disorders years before diagnosis, whereas other individuals experience these symptoms only after diagnosis. Second, in people with prodromal sleep disorders, cardiac sympathetic denervation precedes nigrostriatal degeneration by approximately a decade, whereas in individuals without sleep disorders, these systems degenerate in the opposite sequence. Third, post-mortem studies often reveal bottom-up or top-down gradients of Lewy pathology, consistent with body-first versus olfactory-first origins. This Review provides a critical appraisal of the BvB model, highlighting supporting evidence and current limitations. The article also considers implications for diagnostics, therapy and prevention, and outlines key avenues for future research. The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and post-mortem pathology. Here, Borghammer et al. evaluate the evidence for this model, outline its implications for diagnosis, therapy and prevention, and identify priorities for future research.
{"title":"Brain-first and body-first subtypes of Lewy body disease","authors":"Per Borghammer, Nathalie Van Den Berge, Daniela Berg, Ryosuke Takahashi, Ronald B. Postuma, Jacob Horsager","doi":"10.1038/s41582-026-01241-8","DOIUrl":"10.1038/s41582-026-01241-8","url":null,"abstract":"People with Lewy body disease exhibit heterogeneous clinical symptoms, diverse patterns of neurodegeneration on imaging and variable Lewy body pathology at post-mortem. The brain-first versus body-first (BvB) model provides a unifying framework that may account for much of this variability. According to the BvB model, Lewy pathology originates either in autonomic nerves of the gut or other peripheral neurons (body first) or in the olfactory bulb with subsequent spread to the limbic system (brain first). Both subtypes are thought to begin largely outside the CNS, possibly triggered by exogenous factors such as infectious agents or toxins. The model is supported by several observations. First, some individuals develop autonomic dysfunction and sleep disorders years before diagnosis, whereas other individuals experience these symptoms only after diagnosis. Second, in people with prodromal sleep disorders, cardiac sympathetic denervation precedes nigrostriatal degeneration by approximately a decade, whereas in individuals without sleep disorders, these systems degenerate in the opposite sequence. Third, post-mortem studies often reveal bottom-up or top-down gradients of Lewy pathology, consistent with body-first versus olfactory-first origins. This Review provides a critical appraisal of the BvB model, highlighting supporting evidence and current limitations. The article also considers implications for diagnostics, therapy and prevention, and outlines key avenues for future research. The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and post-mortem pathology. Here, Borghammer et al. evaluate the evidence for this model, outline its implications for diagnosis, therapy and prevention, and identify priorities for future research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"564-580"},"PeriodicalIF":31.2,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-07-14DOI: 10.1038/s41582-026-01247-2
Lisa Kiani
Ebola virus disease is associated with a broad range of long-term neurological sequalae, a new study reports.
一项新的研究报告称,埃博拉病毒病与广泛的长期神经后遗症有关。
{"title":"Neurological symptoms in survivors of Ebola virus disease","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01247-2","DOIUrl":"10.1038/s41582-026-01247-2","url":null,"abstract":"Ebola virus disease is associated with a broad range of long-term neurological sequalae, a new study reports.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 8","pages":"481-481"},"PeriodicalIF":31.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41582-026-01247-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148441130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}